1
|
Cumbo E, De Lucia O, Murgo A, Artusi C, Cimaz R, Caporali R. AB0973 Long term efficacy of intra-articular viscosupplementation with hyaluronic acid in hip osteoarthritis secondary to systemic rheumatic diseases: a preliminary evaluation. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundFew studies have assessed response to intra-articular HA viscosupplementation in patients affected by hip osteoarthirtis secondary to systemic rheumatic diseases (SOA). From in vitro studies we know that the synovial environment in these diseases presents different molecular characteristics in comparison to primary osteoarthritis (POA) in terms of pro-inflammatory activity and therefore in degradation of hyaluronic acid.ObjectivesTo evaluate differences in efficacy and safety of treatment with US-guided intra-articular HA viscosupplementation between a cohort affected by POA and one affected by SOA, with regard to pain assessment and time to arthroplasty.MethodsWe conducted this observational retrospective study on consecutive patients treated with US-guided hip intra-articular injections with Hylan G-F 20 2 ml at the Rheumatology Unit of ASST-Pini-CTO (Milan, Italy) from 2013 to 2021. Joints with active synovitis detected by US examination weren’t treated. VAS pain at baseline and at the end of October 2021 was registered as well as time to the event of hip arthroplasty and adverse reactions.Patients treated had hip pain at least 6 months before treatment and radiological OA assessed by standard hip X-rays no more than 6 months before baseline. Patients included in the SOA group had a diagnosis of rheumatic systemic disease, POA patients had osteoarthritis and any further rheumatological condition was ruled out.Additional clinical features recorded for the SOA patients were clinimetric assessment of disease activity according to SDAI for RA, clinical judgment for PMR, DAPSA for PsA, ASDAS for SpA and medical treatment at baseline.ResultsWe included 55 primary OA patients and 16 systemic rheumatic diseases patients (5 JIA, 5 peripheral SpA, 2 PMR, 1 Axial-Spa, 1 PsA, 2 RA) who had received hip intra-articular HA injection with Hylan G-F 20 2 ml once a month for three consecutive months and then every six month. Mean duration of follow up was 51.1 (± 27.1) months.We observed significant longer treatment survival and lower VAS pain in POA patients at follow up (in absence of significant difference of VAS pain at baseline).In both cohorts we observed a reduction in VAS pain similar to that reported in literature: in the POA a mean reduction of 29.7 (95% CI 23.8-35.6), while in the SOA was noticed a mean reduction of 12.8 (95% CI 1.8-23.7) in absence of significant clinimetric variations over time.We observed higher incidence of local adverse reactions in SOA group (2 cases of post-injection synovitis in the SOA cohort only (12.5%), p 0.04).POA Hips (N=62)SOA Hips (N=16)p-valueTreatment duration, m46.8±30.222.4±22.40.0038HA injections, (N)9.9±5.15.3±3.20.00113 or more HA injections, % (N)85% (53)81% (13)0.70Adverse reactions, % (N)012.5% (2)0.040VAS Pain3.25±1.734.3±1.40.029Total Hip arthroplasty during follow up, % (N)11.2 (7)6.2 (1)1.00Time to arthroplasty, m46.8±30.2260.28ConclusionAccording to our results symptomatic hip SOA patients respond less and with a slightly higher degree of adverse reactions to intra-articular viscosupplementation when compared to POA patients, even if the incidence of these adverse events was similar to that observed in previous studies.We can infere that synovial pro-inflammatory enviroment in rheumatic systemic diseases can reduce efficacy of intra-articular viscosupplementation with hyaluronic acid.References[1]Migliore Alberto et al., «Intra-Articular Injection of Hyaluronic Acid (MW 1,500–2,000 KDa; HyalOne) in Symptomatic Osteoarthritis of the Hip: A Prospective Cohort Study», Archives of Orthopaedic and Trauma Surgery 131, n. 12 (December 2011): 1677–85, https://doi.org/10.1007/s00402-011-1353-y.[2]Thierry Conrozier et al., «Clinical Response to Intra-Articular Injections of Hylan G-F 20 in Symptomatic Hip Osteoarthritis: The OMERACT-OARSI Criteria Applied to the Results of a Pilot Study», Joint Bone Spine 73, n. 6 (December 2006): 705–9, https://doi.org/10.1016/j.jbspin.2006.02.008.Disclosure of InterestsNone declared
Collapse
|
2
|
Ingegnoli F, Ubiali T, Schioppo T, Longo V, Iodice S, Favalli EG, De Lucia O, Murgo A, Bollati V, Caporali R. AB0229 SHORT-TERM EXPOSURE TO OUTDOOR AIR POLLUTANTS AND RHEUMATOID ARTHRITIS ACTIVITY IN METROPOLITAN AREAS IN THE NORTH OF ITALY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Air pollution is believed to cause oxidative stress and systemic inflammation, that could trigger autoimmunity in rheumatoid arthritis (RA). Several epidemiological studies investigated the possible role of air pollution in the outbreak of RA with controversial results. As far as we know, studies on the effects on disease activity of short-term exposure have not been published.Objectives:To evaluate the impact of short-term exposure to air pollutants (daily mean PM10, PM2.5, NO2and O3) on disease activity in patients with RA.Methods:Consecutive patients with RA (ACR/EULAR Criteria 2010) resident in Lombardy (Italy) were enrolled. In each patient Disease Activity Score on 28 joints (DAS28), Simple Disease Activity Index (SDAI) were assessed. Daily PM10, PM2.5, NO2and O3concentrations, estimated by Regional Environmental Protection Agency at municipality resolution, were used to assign short-term exposure from day of visit back to 14 days. Multivariable linear regression models were performed to identify the day of the pollutants independently associated with disease activity indices, adjusting for the variables significant at the univariate analysis. β coefficients were reported for 1 μg/m3increments of pollutants’ concentrations.Results:422 RA patients were enrolled in the study between January and June 2018: 81.5% females, mean age 58.2±13.3 years, mean disease duration 16.1±11.5 years, 27.3% current smokers, 59.5% RF positivity, 54.5% ACPA positivity. Sparse punctual statistically significant negative associations emerged at the multivariate analysis between PM10, PM2.5, NO2and the outcomes, although with very low estimates, whereas positive associations resulted for O3.Afterwards patients were stratified in 3 subgroups according to their ongoing treatment (no therapy, n=25, conventional synthetic Disease Modifying anti-Rheumatic Drugs -DMARDs-, n=108 and biological or targeted synthetic DMARDs, n=289). A statistical significance was found by analysing the influence of therapy on the interaction between PM2.5and DAS28 (Figure below): a positive trend between PM2.5and DAS28 appeared in the first two groups (no therapy, 0.013±0.007, p=0.06 and csDMARDs, 0.006±0.004, p=0.17), whereas a statistically significant inverse association was seen in the b/tsDMARDs group (-0.005±0.002, p=0.01). Therapy interaction was particularly evident in several days before the visit also for O3.Conclusion:The changes of the outcome measures related to the increase of the pollutants’ levels did not reach the minimal clinically important difference, therefore air pollution seems barely relevant on disease activity once the loss of tolerance is established in RA. O3and PM/NO2always exhibit an opposite performance having inversely proportional atmospheric concentrations, whereas the biological role of this substance is still matter of debate and will need further understanding. Therapy seems to be able to interact with the relation between air pollutants and the parameters considered.Disclosure of Interests:Francesca Ingegnoli: None declared, Tania Ubiali: None declared, Tommaso Schioppo: None declared, Valentina Longo: None declared, Simona Iodice: None declared, Ennio Giulio Favalli Consultant of: Consultant and/or speaker for BMS, Eli-Lilly, MSD, UCB, Pfizer, Sanofi-Genzyme, Novartis, and Abbvie, Speakers bureau: Consultant and/or speaker for BMS, Eli-Lilly, MSD, UCB, Pfizer, Sanofi-Genzyme, Novartis, and Abbvie, Orazio De Lucia: None declared, Antonella Murgo: None declared, Valentina Bollati: None declared, Roberto Caporali Consultant of: AbbVie; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Celgene; Bristol-Myers Squibb; Pfizer; UCB, Speakers bureau: Abbvie; Bristol-Myers Squibb; Celgene; Lilly; Gilead Sciences, Inc; MSD; Pfizer; Roche; UCB
Collapse
|
3
|
Ingegnoli F, Scotti I, Schioppo T, Ubiali T, Marano G, Boracchi P, De Lucia O, Murgo A, Caporali R. SAT0090 EFFECTS OF ADHERENCE TO MEDITERRANEAN DIET ON RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) SCORE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Mediterranean diet (MD) is a well-balanced, nutritionally adequate and potentially anti-inflammatory diet that encompasses all food groups. Presently, there are conflicting data about the benefits of MD in rheumatoid arthritis (RA). Not enough evidence support a role of MD in the prevention and treatment of RA, and a modest impact of MD on laboratory parameters has been described. Greater effect on subjective aspects of the disease such as joint pain, morning stiffness, and fatigue was reported.Objectives:To investigate whether the adherence to MD affects RA perception as measured by Rheumatoid Arthritis Impact of Disease (RAID) score.Methods:Consecutive patients <65 years with RA attending our outpatient clinic were enrolled in this cross-sectional study. For each patient we collected: 1) RAID that consists of 7 single-item domains (pain, functional disability, fatigue, sleep, physical well-being, emotional well-being and coping), each rated by patients on an 11-point numerical rating scale from 0 (best) to 10 (worst) [1], and 2) MD score, a self-reported questionnaire that evaluates the adherence to MD through the consumption of 11 food groups, ranging from 0 (no adherence) to 55 (high adherence) [2]. Univariate analysis was performed using MD score as independent variable. Moreover, to evaluate the adjusted relationship between the single item of RAID and MD score, a multiple regression model was used.Results:205 RA patients were enrolled: median age at visit 53 (q1-q3: 44-59) years, female 80.5 %. The median MD and RAID score were 35 (q1-q3: 32-39) and 2.42 (q1-q3: 0.63-4.51) respectively.RAID total score had a statistically significant negative relationship with MD score (regression coefficient -0.08; p-value=0.016). Concerning the single RAID items, a statistically significant negative association was found for pain (regression coefficient -0.08; p-value=0.025), functional disability (regression coefficient -0.13; p-value<0.001), sleep (regression coefficient -0.08; p-value=0.041), physical well-being (regression coefficient -0.08; p-value=0.027) and coping (regression coefficient -0.11; p-value=0.008).Multiple regression analysis to evaluate the relationship between significant RAID items and MD score did not show any statistical significance as all items are strongly related to each other.Conclusion:To our knowledge, this is the first study addressing the relationship between the adherence to MD and the perception of RA impact. A better MD adherence was associated with lower self-reported composite total RAID score as well as lower pain, functional disability, sleep, physical well-being and coping. The effect of MD adherence on overall RAID is relevant but, at the same time, a prominent effect of one single item on the others could not be documented. This study confirmed the importance of non-pharmacological interventions, such as diet, in RA management.References:[1] Gossec L, et al. Ann Rheum Dis 2011;70(6):935-42.[2] Panagiotakos DB, et al. Nutr Metab Cardiovasc Dis 2006;16(8):559-68.Disclosure of Interests:Francesca Ingegnoli: None declared, Isabella Scotti: None declared, Tommaso Schioppo: None declared, Tania Ubiali: None declared, Giuseppe Marano: None declared, Patrizia Boracchi: None declared, Orazio De Lucia: None declared, Antonella Murgo: None declared, Roberto Caporali Consultant of: AbbVie; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Celgene; Bristol-Myers Squibb; Pfizer; UCB, Speakers bureau: Abbvie; Bristol-Myers Squibb; Celgene; Lilly; Gilead Sciences, Inc; MSD; Pfizer; Roche; UCB
Collapse
|
4
|
Ughi N, Schioppo T, Scotti I, Merlino V, Murgo A, De Lucia O, Fautrel B, Guillemin F, Christensen R, Ingegnoli F. Translation and cross-cultural adaptation into Italian of the self-administered FLARE-RA questionnaire for rheumatoid arthritis. Reumatismo 2020; 72:21-30. [PMID: 32292018 DOI: 10.4081/reumatismo.2020.1230] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 01/31/2020] [Indexed: 11/23/2022] Open
Abstract
The aim was to provide a translation into Italian with cross-cultural adaptation of the French FLARE-Rheumatoid Arthritis (RA) questionnaire, and to test its acceptability, feasibility, reliability and construct validity in a single-centre cohort study. The French version of the FLARE-RA questionnaire was cross-culturally adapted and translated into Italian following an established forward-backward translation procedure, with independent translations and backtranslations. To validate the Italian version we tested the internal validity with Cronbach's alpha, test-retest reliability with the intraclass correlation coefficient, agreement between assessments with Bland-Altman plots and construct validity with Spearman's correlation coefficients. The questionnaire was tested on 283 consecutive RA outpatients (mean age 56.1±13.9 years, 226/283 females, median disease duration 12.6 years ranging from 0.2 to 70.6). For the global score (11 items) the Cronbach's alpha coefficient was 0.94. The intraclass correlation coefficient was 0.87 (95% CI, 0.76-0.96). The correlation of FLARE-RA global score was 0.59 (95% CI, 0.50-0.66) with the Disease Activity Score on 28 joints, 0.63 (95% CI, 0.55-0.71) with the Simplified Disease Activity Index, 0.77 (95% CI, 0.71-0.83) with the RA Impact of Disease and 0.67 (95% CI, 0.59-0.73) with the Health Assessment Questionnaire. The Italian version of the FLARE-RA is feasible, brief and easy to administer. The translated and cross-cultural adapted showed accordingly to be valid and reliable. This questionnaire has some practical advantages, such as clarity, comprehensiveness, simplicity, and a minimum filling time. The development of cross-cultural adapted questionnaires in different languages is of pivotal importance to obtain standardized and comparable data across countries.
Collapse
Affiliation(s)
- N Ughi
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano.
| | - T Schioppo
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano.
| | - I Scotti
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano.
| | - V Merlino
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano.
| | - A Murgo
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano.
| | - O De Lucia
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano.
| | - B Fautrel
- Department of Rheumatology, IMIDIATE Clinical Research Network, Pitié Salpêtrière Hospital, Pierre et Marie Curie University, Paris 6, Sorbonne University, GRC-08 (EEMOIS), Paris.
| | - F Guillemin
- Inserm Clinical Epidemiology Center 1433, Brabois University Hospital, Vandoeuvre-lès-Nancy.
| | - R Christensen
- Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital and Department of Rheumatology, Odense University Hospital, Frederiksberg.
| | - F Ingegnoli
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano.
| |
Collapse
|
5
|
Schioppo T, Scalone L, Cozzolino P, Mantovani L, Cesana G, De Lucia O, Murgo A, Ingegnoli F. Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens. Reumatismo 2019; 71:62-67. [PMID: 31309775 DOI: 10.4081/reumatismo.2019.1190] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Accepted: 03/07/2019] [Indexed: 11/23/2022] Open
Abstract
Systemic sclerosis (SSc)-related Raynaud's phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months' follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months). The two different IV ILO regimens (the most appropriate regimen was decided according to patients' characteristics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy.
Collapse
Affiliation(s)
- T Schioppo
- Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Penatti A, Facciotti F, De Lucia O, Murgo A, Pierannunzii L, Marcello T, Abrignani S, Meroni P, Geginat J. OP0224 Th17 Cells and TFH Cells and their Cytokine Products Are Enriched in the Synovium of Rheumatoid Arthritis Patients and Correlate with Disease Activity. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Valcamonica E, Chighizola CB, Comi D, De Lucia O, Pisoni L, Murgo A, Salvi V, Sozzani S, Meroni PL. Levels of chemerin and interleukin 8 in the synovial fluid of patients with inflammatory arthritides and osteoarthritis. Clin Exp Rheumatol 2014; 32:243-250. [PMID: 24529071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2012] [Accepted: 11/12/2013] [Indexed: 06/03/2023]
Abstract
OBJECTIVES Chemerin and interleukin (IL)-8 are pro-inflammatory mediators whose role in joint inflammation and cartilage degradation has been demonstrated in in-vitro findings. Studies on their presence in synovial fluid (SF) samples may offer further information on their pathogenic role. The aim of this study was to investigate SF chemerin and IL-8 levels in patients with different joint diseases. METHODS 37 patients were enrolled: 18 with rheumatoid arthritis (RA), 8 with psoriatic arthritis (PsA) and 11 with osteoarthritis (OA). 41 SF samples were obtained by arthrocentesis in case of knee synovitis. Serum samples were obtained from 13 patients (4 with RA, 6 with PsA and 3 with OA) at the time of arthrocentesis. Chemerin, IL-8, TNF-α and IL-6 levels were measured using commercially available ELISA kits. Immunohistochemical analysis of synovial RA specimens was also performed. RESULTS No difference in chemerin SF levels emerged between patients with immune-mediated inflammatory arthritides and those with OA (p=0.0656), while subjects with inflammatory arthritis displayed significantly higher levels of SF IL-8 compared to OA (p=0.0020). No significant difference emerged across the three conditions in the serum levels of both chemerin and IL-8. IL-8 strongly correlated with inflammatory markers as ESR, CRP, IL-6 and TNF-α. CONCLUSIONS We observed similar chemerin SF and serum levels in the three conditions. Although flawed by some limitations, our findings support the emerging concept of OA as an inflammatory disorder. However the increased IL-8 levels we described in patients with inflammatory arthritis suggest a selective involvement of this pro-inflammatory and angiogenic cytokine in these conditions.
Collapse
Affiliation(s)
- E Valcamonica
- Division of Rheumatology, Istituto G. Pini, Milan, Italy and Doctorate Course in Genetics, Oncology and Clinical Medicine, University of Siena, Siena, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
De Lucia O, Comi D, Valcamonica E, Pisoni L, Murgo A, Paresce E, Chighizola C, Meroni P. AB0998 Medium and high molecular weight hyaluronic acid injected in hip joint by US-guided technique in patients with primary or secondary hip osteoarthritis: A 2 year observational study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Ingegnoli F, Gualtierotti R, Schioppo T, Orenti A, Boracchi P, Lubatti C, Murgo A, Zeni S, Mastaglio C, Galbiati V, Monti G, Grossi C, Borghi O, Rosenberg W, Meroni PL. FRI0403 How early starts increased collagen synthesis in systemic sclerosis? Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Saglimbene V, D'Alonzo D, Ruospo M, Vecchio M, Natale P, Gargano L, Nicolucci A, Pellegrini F, Craig JC, Triolo G, Procaccini DA, Santoro A, Di Giulio S, La Rosa S, Murgo A, Di Toro Mammarella R, Sambati M, D'Ambrosio N, Greco V, Giannoccaro G, Flammini A, Boccia E, Montalto G, Pagano S, Amarù S, Fici M, Lumaga GB, Mancini E, Veronesi M, Patregnani L, Querques M, Schiavone P, Chimienti S, Palumbo R, Di Franco D, Della Volpe M, Gori E, Salomone M, Iacono A, Moscoloni M, Treglia A, Casu D, Piras AM, Di Silva A, Mandreoli M, Lopez A, Quarello F, Catizone L, Russo G, Forcellini S, Maccarone M, Catucci G, Di Paolo B, Stingone A, D'Angelo B, Guastoni C, Pasquali S, Minoretti C, Bellasi A, Boscutti G, Martone M, David S, Schito F, Urban L, Di Iorio B, Caruso F, Mazzoni A, Musacchio R, Andreoli D, Cossu M, Li Cavoli G, Cornacchiari M, Granata A, Clementi A, Giordano R, Guastoni C, Barzaghi W, Valentini M, Hegbrant J, Tognoni G, Strippoli GFM. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]. G Ital Nefrol 2013; 30:gin/00072.21. [PMID: 23832463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are the most used treatment option. In observational studies, higher haemoglobin (Hb) levels (around 11-13 g/dL) are associated with improved survival and quality of life compared to Hb levels around 9-10 g/dL. Randomized studies found that targeting higher Hb levels with ESA causes an increased risk of death, mainly due to adverse cardiovascular outcomes. It is possible that this is mediated by ESA dose rather than haemoglobin concentration, although this hypothesis has never been formally tested. METHODS We present the protocol of the Clinical Evaluation of the Dose of Erythropoietins (C.E. DOSE) trial, which will assess the benefits and harms of a high versus a low ESA dose therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD). This is a randomized, prospective open label blinded end-point (PROBE) design trial due to enroll 900 haemodialysis patients. Patients will be randomized 1:1 to 4000 UI/week i. v. versus 18000 UI/week i. v. of epoetin alfa, beta or any other epoetin in equivalent doses. The primary outcome of the trial is a composite of cardiovascular events. In addition, quality of life and costs of these two strategies will be assessed. The study has been approved and funded by the Italian Agency of Drugs (Agenzia Italiana del Farmaco (AIFA)) within the 2006 funding plan for independent research on drugs (registered at www.clinicaltrials.gov (NCT00827021)).
Collapse
|
11
|
Sarantopoulos J, Lenz H, LoRusso P, Shibata S, Kummar S, Mulkerin D, Ramanathan RK, Mita MM, O'Rourke P, Remick SC, Goel S, Gutierrez M, Ramalingam SS, Murgo A, Davies AM, Mani S, Boni J, Shapiro M, Ivy SP, Takimoto CH. Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Justice R, Ibrahim A, Murgo A, Pazdur R. 32 The point of view of FDA. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71736-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
13
|
Duffy AG, Melillo G, Turkbey B, Allen D, Choyke PL, Chen C, Raffeld M, Doroshow JH, Murgo A, Kummar S. A pilot trial of oral topotecan (TPT) in patients with refractory advanced solid neoplasms expressing HIF-1α. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13518] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. Hum Gene Ther 2010; 20:453-64. [PMID: 19215191 DOI: 10.1089/hum.2008.172] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The highly aggressive cancer syndrome of female mice carrying a p53 knockout allele and a rat HER-2/neu (Neu) transgene (BALB-p53Neu) can be prevented by a cell vaccine presenting three components: Neu, interleukin (IL)-12 production, and allogeneic major histocompatibility complex (MHC) alleles (Triplex cell vaccine). Here we tested a second-generation Triplex DNA-based vaccine (Tri-DNA), consisting of the combination of three gene components (a transmembrane-extracellular domain fragment of the Neu gene, IL-12 genes, and the H-2D(q) allogeneic MHC gene), carried by separate plasmids. The Tri-DNA vaccine was at least as effective as the Triplex cell vaccine for cancer immunoprevention, giving a similar delay in the onset of mammary cancer and complete protection from salivary cancer. Both vaccines induced anti-Neu antibodies of the murine IgG2a isotype at similar levels. The Tri-DNA vaccine gave more restricted immunostimulation, consisting of a fully helper T cell type 1 (Th1)-polarized response, with effective production of interferon (IFN)-gamma in response to the vaccine but no spontaneous production, and no induction of anti-Neu IgG3 antibodies. On the other hand, the Triplex cell vaccine induced both Th1 and Th2 cytokines, a strong increase in spontaneous IFN-gamma production, and high levels of IgG3 antibodies recognizing Neu-positive syngeneic cells. In conclusion, the Tri-DNA vaccine is as effective as Triplex cell vaccine, exploiting a more restricted immune stimulation.
Collapse
Affiliation(s)
- C De Giovanni
- Cancer Research Section, Department of Experimental Pathology, Alma Mater Studiorum, University of Bologna, I-40126 Bologna, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ho J, Strevel E, Chau N, Pond G, Murgo A, Ivy P, Siu L. 382 POSTER Comparison of phase I trial (P1T) abstract quality between the EORTC-NCI-AACR and ASCO meetings. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72316-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
16
|
De Lucia O, Paresce E, Murgo A, Epis O, Pisoni L, Schito E, Valcamonica E, Piana C, Fantini F. [Simultaneous ultrasonography and arthroscopy for the study of the joint environment: indications and limits]. Reumatismo 2007; 59:146-52. [PMID: 17603695 DOI: 10.4081/reumatismo.2007.146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Arthroscopy is a mini-invasive technique that allows the direct observation of the joint cavity and the execution of diagnostic and therapeutic procedures; arthroscopy needs a very long learning-time curve as well as dedicated spaces and instruments. Ultrasonography is an imaging technique that enables to perform an immediate extension of the standard physical examination. The opportunity to visualize soft tissues, to obtain multiplanar and dynamic images in real time makes this practice easy repeatable at low costs. Ultrasonography allows to detect a variety of changes during inflammatory processes. The wide experience in arthroscopy of rheumatic patients acquired through the years by our team at the G. Pini Institute led us to study in vivo, during arthroscopy, the correspondence between arthroscopic and ultrasonographic images. Up to now three knee arthroscopies have been conducted with the double equipment (ultrasonographic and arthroscopic devices) in operating room. In our experience, the combination of the two methods in operating room may improve the validation of ultrasonography with arthroscopy as gold standard, helps to train the ultrasonographer to give immediate answers in order to clear the doubts aroused by ultrasonographic images; it also allows the arthroscopist to visualize the deeper layers of the synovial membrane making double guided targeted biopsies possible. Limits are the complexity of the procedure (instruments, operators, spaces, training of the doctors), the loose of power-doppler signal with the blood tourniquet and the always difficult evaluation of cartilage.
Collapse
Affiliation(s)
- O De Lucia
- U.O. e Cattedra di Reumatologia, Istituto Ortopedico G. Pini, Milano, Italia.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Ji J, Redon C, Pommier Y, Kinders R, Parchment R, Hollingshead M, Yang S, Murgo A, Tomaszewski J, Doroshow J. Poly-adeninosinediphosphate-ribose polymerase inhibitors as sensitizers for therapeutic treatments in human tumor and blood mononuclear cells. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14024 Background: Poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) is a molecular sensor of DNA breaks that facilitates DNA repair and controls genomic stability. Treatment with single doses of ABT-888, a novel potent PARP-1 inhibitor, reduced PAR levels in peripheral blood mononuclear cells (PBMCs) and tumor biopsies in an on-going Phase-0 trial at the NIH Clinical Center. As a corollary to this study, we investigated whether ABT-888 can act as a sensitizer for radiation therapy and chemotherapy in human cancer cell culture, xenograft tumors and PBMCs to support future combination clinical trials. Methods: Inhibition of PARP-1 by ABT-888 was determined by a quantitative PAR chemiluminescence immunoassay validated for the Phase 0 trial. Since gamma-H2AX (?-H2AX) is a marker of DNA damage, we also developed and validated ?H2AX assays to monitor the effects of PARP-1 inhibition during treatment with Topo I inhibitors and radiation. Human monocytic leukemia (THP-1) and breast carcinoma (MCF-7) cell lines were treated with Topo I inhibitors including indenoisoquinoline, camptothecin and topotecan or irradiated with 0.5 to 10 Gy in the presence of ABT 888. We further evaluated these effects in human blood ex vivo to confirm the observations made in cell culture. Results: We found that ABT-888 inhibited PAR, but did not significantly increase DNA damage. Combination of ABT-888 with a Topo I inhibitor produced over 275% increase of DNA damage in THP-1 leukemia cells compared to indenoisoquinoline alone. ?H2AX foci per cell were 9.5 ± 0.8 in MCF-7 treated with 0.5 Gy/50 nM ABT-888 in comparison to 4.0 ± 0.6 with radiation alone. When whole blood was treated in the presence of ABT-888, camptothecin- induced DNA damage in PBMCs was also increased 2–3 fold, with maximum ?H2AX expression at 2 hours post treatment. Conclusions: We conclude that ABT-888 is a highly potent PARP-1 inhibitor that can enhance the DNA damaging effects of chemotherapy and radiation therapy of human cancer. Funded by NCI Contract N01-CO-12400. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Ji
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | - C. Redon
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | - Y. Pommier
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | - R. Kinders
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | - R. Parchment
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | | | - S. Yang
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | - A. Murgo
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| | | | - J. Doroshow
- SAIC-Frederick; National Cancer Institute, Bethesda, MD
| |
Collapse
|
18
|
Yang SX, Nguyen D, Steinberg SM, Ji J, Parchment R, Kinders R, Kummar S, Gutierrez M, Murgo A, Tomaszewski JE, Doroshow JH. Quantitative immunohistochemical detection of gamma-H2AX in paraffin-embedded human tumor samples at National Clinical Target Validation Laboratory. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10565 Background: DNA double-strand breaks (DSBs) caused by exposure to DNA damaging agents initiate phosphorylation of histone H2AX to form gamma-H2AX, which is considered a surrogate marker of DSBs. However, it is a challenge to quantitatively measure gamma-H2AX in clinical samples such as tumor biopsies. The aim of this study was to develop an immunohistochemical detection method for gamma-H2AX and to quantitatively evaluate the levels of gamma-H2AX in paraffin-embedded tumor samples. Methods: Human breast cancer MCF-7 cells were treated with the topoisomerase I inhibitor irinotecan at 1 μM or vehicle for 1 h, and fixed in 10% neutral buffered formalin and embedded in paraffin. Staining with gamma-H2AX antibody was performed on sections of treated MCF-7 cells, tumor specimens, and biopsies at baseline and after doxorubicin-containing chemotherapy from cancer patients. Numbers of foci and level of gamma-H2AX expression per tumor nucleus were determined by manual counting under a light microscope and an Automated Cellular Imaging System. Results: There was a rise in the mean numbers of nuclear foci and intensity of gamma-H2AX in MCF-7 cells treated with irinotecan versus vehicle (19.9 ± 2.7 vs. 9.95 ± 3.6; P < 0.0001 and 61.2 ± 8.5 vs. 16.2 ± 13.6; P < 0.0001 by Wilcoxon rank sum test). The level of gamma-H2AX foci in human tumor samples was 18.8 ± 13.1, 44.8 ± 14.5, 51.2 ± 20.8, or 69.7 ± 21.2 in carcinomas of the breast, colon, ovary, or prostate. In a patient with stable disease, levels of gamma-H2AX foci were 62.7 ± 26.9 at baseline and 67.2 ± 25.3 after doxorubicin-containing regimen chemotherapy. Conclusions: Our data suggest that the quantitative immunohistochemical detection of gamma-H2AX levels is facilitated by a digital imaging system, and is a reliable method to measure the effects of DNA damaging agents in cells and paraffin-embedded human tumor samples. Its application may help evaluate tumor response to various DNA damaging agents currently in the clinic and those presently undergoing clinical development. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. X. Yang
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - D. Nguyen
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - S. M. Steinberg
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - J. Ji
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - R. Parchment
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - R. Kinders
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - S. Kummar
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - M. Gutierrez
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - A. Murgo
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - J. E. Tomaszewski
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| | - J. H. Doroshow
- NCI, Bethesda, MD; SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD
| |
Collapse
|
19
|
George R, Lahti J, Ingle M, Krailo M, Blaney S, Adamson P, Murgo A, Kidd V, Diller L. Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): A Children's Oncology Group Study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9565] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9565 Background: Loss of caspase-8 expression causes resistance to apoptosis-inducing agents and potentiates metastasis in NBL. In vitro treatment of NBL cell lines with DAC results in increased caspase-8 expression and enhanced apoptosis following exposure to DOX. As a component of a pediatric phase 1 study, we evaluated low-dose DAC with DOX and CTX in a cohort of children with relapsed NBL. Promoter specific DNA methylation in peripheral blood mononuclear cells (PBMC) was studied. Methods: Patients received a 1-hour infusion of DAC, 5 mg/m2, daily on days 0–6, followed on day 7 by 45 mg/m2 of DOX (with dexrazoxane) and 1 g/m2 of CTX. All patients received G-CSF. Cycles were repeated every 28 days. Methylation-specific and quantitative PCR were used to measure promoter-specific DNA methylation in PBMC prior to and after DAC (day 7 and day 28). Results: Twelve patients with recurrent NBL (median age 9 years, 10 males) were enrolled. DAC/DOX/CTX was well tolerated with grade 4 myelosuppression being the predominant toxicity. Grade 4 neutropenia, median 11 days duration, occurred in 10 pts and grade 4 thrombocytopenia, median 10 days, in 7 patients. Eight patients had progressive disease after = 2 courses of therapy. The remaining 4 patients had stable disease with 5 to 8 courses. Methylation and subsequent demethylation (40–90% decreased methylation) of the MAGE-1 promoter was detected before and after DAC respectively, in PBMC from 6 of 9 patients analyzed to date. Re-expression of MAGE-1 mRNA was also demonstrated in post treatment samples. Caspase-8 demethylation was not detected in PBMC; nor was hypermethylation of caspase-8 detected in pre-treatment PBMC, possibly due to low tumor burden in blood. Conclusions: DAC in combination with cytotoxic chemotherapy was relatively well tolerated in heavily pre-treated children with relapsed NBL. Low-dose DAC induces demethylation and re-expression of MAGE-1 in PBMC, and may be a potential surrogate marker of demethylation within tumor cells. The use of low dose DAC in combination with other agents warrants further study in NBL. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. George
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - J. Lahti
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - M. Ingle
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - M. Krailo
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - S. Blaney
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - P. Adamson
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - A. Murgo
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - V. Kidd
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| | - L. Diller
- Dana-Farber Cancer Institute, Boston, MA; St Jude Children's Research Hospital, Memphis, TN; Children's Oncology Group, Arcadia, CA; Texas Children's Cancer Center, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; National Cancer Institute, Bethesda, MD
| |
Collapse
|
20
|
Pisoni L, Murgo A, Paresce E, Zeni S, Fantini F. Effectiveness and safety of leflunomide in the clinical practice. A different experience. Clin Exp Rheumatol 2007; 25:115; author reply 116. [PMID: 17418002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
|
21
|
Liu B, Barrett T, Choyke P, Maynard K, Wright J, Kummar S, Murgo A, Doroshow J, Gutierrez M. A phase II study of BAY 43–9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17119] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17119 Background: Sorafenib is an inhibitor of multiple kinases including Raf-1 (C-Raf), b-Raf and pro-angiogenic tyrosine kinases (VEGFR-2/3 and PDGFR-β) and showed preclinical activity against NSCLC cell lines. Its anti-tumor activity may be attributable to inhibition of proliferative signaling through the RAS/Raf/MEK/ERK pathway and its anti-angiogenic effects. In NSCLC, the proliferation signaling of the Ras/Raf/MEK/ERK pathway is increased due to the increase in K-ras mutations. We initiated a single agent sorafenib trial in patients (pts) with relapsed NSCLC to assess clinical response and translational endpoints in tumor biopsies. Methods: This phase 2 trial uses a two-stage design targeting an objective response rate (RR) which can rule out 5% in favor of a more desirable 20% RR. Eligibility criteria: Pts with recurrent NSCLC with measurable disease who have received only one prior chemotherapy regimen, ECOG 0–1. Pts receive Sorafenib 400 mg bid continuously on 28-day cycle. Responses were evaluated every 8 weeks (wks) according to RECIST criteria. Dynamic contrast enhanced MRI (DCE-MRI) and tumor biopsy are performed before cycle 1 and at C1D15 to study early changes in tumor vascularity and translational endpoints. Results: 6 pts are evaluable for toxicity and 5 pts are evaluable for response. Best Response: 1PR (41% tumor reduction at wk 8, remained in PR until wk 28), 1 PR (unconfirmed) at wk 3, 2SD (16 and 19 wks respectively) and 1PD after 8 wks of treatment. Skin toxicity: Acne like drug-related rash (5 pts), hand-foot syndrome (6 pts), keratoacanthoma (1pt) and vasculitis (1pt). All skin toxicities are G1 or G2 and have responded to temporary withdrawal of Sorafenib and supportive care. Hypertension occurred in 1 pt (G2). No G4 toxicities have been observed. G3 toxicities include: anemia (1 pt), hyponatremia (2 pts), and nausea (1 pt). DCE-MRI results: 1 pt on C1D15 showed decrease in permibility parameters (ktrans and kep) and tumor size. DCE-MRI from the other 2 pts (1 PD, 1 SD for 16 weeks) showed no decrease in the permeability parameters. Conclusions: Sorafenib appears to be well-tolerated and active against relapsed NSCLC. Preliminary evidence of objective response warranting second stage accrual. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Liu
- National Cancer Institute, Bethesda, MD
| | | | - P. Choyke
- National Cancer Institute, Bethesda, MD
| | | | - J. Wright
- National Cancer Institute, Bethesda, MD
| | - S. Kummar
- National Cancer Institute, Bethesda, MD
| | - A. Murgo
- National Cancer Institute, Bethesda, MD
| | | | | |
Collapse
|
22
|
Dematteo RP, Antonescu CR, Chadaram V, You YN, McCall L, Maki R, Murgo A, Demetri G, Pisters P, Brennan MF. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9009] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. P. Dematteo
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - C. R. Antonescu
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - V. Chadaram
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - Y. N. You
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - L. McCall
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - R. Maki
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - A. Murgo
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - G. Demetri
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - P. Pisters
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| | - M. F. Brennan
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; American Coll of Surgeons Oncology Group, Durham, NC; CTEP, Bethesda, MD; Dana-Farber Cancer Inst, Boston, MA; MD Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
23
|
Donovan EA, Ryan Q, Acharya M, Chung E, Trepel J, Maynard K, Sausville E, Murgo A, Melillo G, Conley B. Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Q. Ryan
- National Cancer Institute, Bethesda, MD
| | | | - E. Chung
- National Cancer Institute, Bethesda, MD
| | - J. Trepel
- National Cancer Institute, Bethesda, MD
| | | | | | - A. Murgo
- National Cancer Institute, Bethesda, MD
| | | | - B. Conley
- National Cancer Institute, Bethesda, MD
| |
Collapse
|
24
|
Hudes GR, Celano P, Torti F, Tabatabai A, Murgo A, Hussain A. Phase II study of weekly paclitaxel (PAC) and bryostatin-1 (BRYO) in hormone refractory prostate cancer (HRPC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4714] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. R. Hudes
- Fox Chase Cancer Ctr, Philadelphia, PA; The Cancer Ctr at GBMC, Baltimore, MD; Comp Cancer Ctr Wake Forest Univ, Winston-Salem, NC; York Cancer Ctr, York, PA; National Cancer Institute - CTEP, Rockville, MD; Univ of Maryland Cancer Ctr, Baltimore, MD
| | - P. Celano
- Fox Chase Cancer Ctr, Philadelphia, PA; The Cancer Ctr at GBMC, Baltimore, MD; Comp Cancer Ctr Wake Forest Univ, Winston-Salem, NC; York Cancer Ctr, York, PA; National Cancer Institute - CTEP, Rockville, MD; Univ of Maryland Cancer Ctr, Baltimore, MD
| | - F. Torti
- Fox Chase Cancer Ctr, Philadelphia, PA; The Cancer Ctr at GBMC, Baltimore, MD; Comp Cancer Ctr Wake Forest Univ, Winston-Salem, NC; York Cancer Ctr, York, PA; National Cancer Institute - CTEP, Rockville, MD; Univ of Maryland Cancer Ctr, Baltimore, MD
| | - A. Tabatabai
- Fox Chase Cancer Ctr, Philadelphia, PA; The Cancer Ctr at GBMC, Baltimore, MD; Comp Cancer Ctr Wake Forest Univ, Winston-Salem, NC; York Cancer Ctr, York, PA; National Cancer Institute - CTEP, Rockville, MD; Univ of Maryland Cancer Ctr, Baltimore, MD
| | - A. Murgo
- Fox Chase Cancer Ctr, Philadelphia, PA; The Cancer Ctr at GBMC, Baltimore, MD; Comp Cancer Ctr Wake Forest Univ, Winston-Salem, NC; York Cancer Ctr, York, PA; National Cancer Institute - CTEP, Rockville, MD; Univ of Maryland Cancer Ctr, Baltimore, MD
| | - A. Hussain
- Fox Chase Cancer Ctr, Philadelphia, PA; The Cancer Ctr at GBMC, Baltimore, MD; Comp Cancer Ctr Wake Forest Univ, Winston-Salem, NC; York Cancer Ctr, York, PA; National Cancer Institute - CTEP, Rockville, MD; Univ of Maryland Cancer Ctr, Baltimore, MD
| |
Collapse
|
25
|
Abrams PL, Egorin MJ, Ramanathan RK, Parise RA, Lagattuta TF, Hayes M, Peng B, Ivy SP, Murgo A, Remick S. Intrapatient consistency of imatinib pharmacokinetics (PK) in patients (pts) with advanced cancers. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. L. Abrams
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - M. J. Egorin
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - R. K. Ramanathan
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - R. A. Parise
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - T. F. Lagattuta
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - M. Hayes
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - B. Peng
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - S. P. Ivy
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - A. Murgo
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| | - S. Remick
- University of Pittsburgh Cancer Institute, Pittsburgh, PA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Institute/CTEP, Rockville, MD; Comp Cancer Ctr at Case Western Reserve University, Cleveland, OH
| |
Collapse
|
26
|
Villalona-Calero MA, Otterson G, Wientjes G, Murgo A, Jensen R, Yeh T, Chen D, Song S, Grever M, Au J. P-229 Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2003. [DOI: 10.1016/s0169-5002(03)92198-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Murgo A, Paresce E, Fantini F. [Arthroscopic synovectomy in chronic inflammatory rheumatism: clinical and functional aspects]. Reumatismo 2003; 55:39-44. [PMID: 12649699 DOI: 10.4081/reumatismo.2003.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
By now many authors regard arthroscopic synovectomy an integral part of therapeutic treatment of many rheumatic diseases with favourable results on post operating course and clinical picture in the long term. The pathologic synovial tissue during articular inflammatory rheumatism is well known to have a damaging effect responsible of early cartilage injury, as well as symptomatic action (e.g. articular stiffness, effusion, pain, functional limitation). Therefore to value the removal of such a tissue you should think of the secondary prevention of cartilage injury, besides the symptomatic point of view. Since 1996 we performed 190 arthroscopic synovectomy, the adopted criteria of judgement were: pain (spontaneous, during active and passive movements), effusion or swelling presence, articular range and cartilage state (evaluated during arthroscopy according to Outerbridg's classification). 70% of the cases showed good results and six years later the beginning of this activity we retain arthroscopic synovectomy as a valid help in articular inflammatory rheumatism treatment.
Collapse
Affiliation(s)
- A Murgo
- Dipartimento e Cattedra di Reumatologia, Istituto Ortopedico G. Pini, Università degli Studi di Milano, Italia.
| | | | | |
Collapse
|
28
|
Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest New Drugs 2002; 19:245-7. [PMID: 11561682 DOI: 10.1023/a:1010676719178] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, is a protein kinase C (PKC) modulator which has shown both preclinical and clinical activity in lymphoid malignancies. We conducted a phase II trial of bryostatin 1 administered at a dose of 120 microg/m2 by 72-h continuous infusion every 2 weeks in patients with relapsed multiple myeloma. Treatment was well tolerated with myalgias constituting the primaray toxicity. There were no responses in nine evaluable patients. The preclinical anti-lymphoid activity is strong enough to support further exploration of bryostatin 1 in different schedules and in combination therapy for multiple myeloma.
Collapse
Affiliation(s)
- M L Varterasian
- Karmanos Cancer Institute and Wayne State University, Detroit, MI, USA.
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
BACKGROUND Cephalotoxine esters, including homoharringtonine (HHT), have shown encouraging activity in leukemia in initial studies in China and in later studies in the U.S. METHODS The authors conducted a review of the literature to examine the studies pertinent to HHT in relation to preclinical studies and Phase I-II trials in patients with hematologic malignancies and solid tumors. RESULTS HHT and analogues appear to induce differentiation and apoptosis. Studies from China reported high response rates in patients with leukemia. Trials in the U.S. using short HHT infusions (3-4 mg/m(2) daily for 5 days) resulted in a high incidence of cardiovascular complications that were reduced using continuous infusion schedules of 3-7 mg/m(2) daily for 5-7 days initially, and later lower dose schedules of 2.5 mg/m(2) daily for 7-14 days. Results in solid tumors were negative. However encouraging results were reported in patients with acute myeloid leukemia, myelodysplastic syndrome, acute promyelocytic leukemia, and, most important, chronic myeloid leukemia (CML). In CML patients, HHT has been investigated alone and in combination with interferon-alpha and low-dose cytarabine in late and early chronic phases, with positive results. Additional areas of interest include the potential use of HHT for the treatment of central nervous system leukemia, polycythemia vera, and other nonmalignant conditions such as malaria. New semisynthetic preparations and HHT derivatives that bypass multidrug resistance may improve the efficacy and toxicity profiles, and broaden the range of antitumor efficacy. CONCLUSIONS HHT and its derivatives appear to have promising activity in hematologic malignancies, a finding that needs to be pursued.
Collapse
Affiliation(s)
- H M Kantarjian
- Department of Leukemia, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | |
Collapse
|
30
|
Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs 2001; 19:13-20. [PMID: 11291829 DOI: 10.1023/a:1006432012394] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF) is a semisynthetic illudin analog with broad in vitro anti-neoplastic activity. In this leukemia phase I study, we investigated the toxicity profile and activity of Irofulven in patients with primary refractory or relapsed acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or myelodysplastic syndromes (MDS). Irofulven was given as an intravenous infusion over five minutes daily for five days. The starting dose was 10 mg/m2/day (50 mg/m2/course). Courses were scheduled to be given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty patients [AML: 17 patients; MDS: one patient; ALL: one patient; mixed lineage acute leukemia: one patient] were treated. Nausea, vomiting, hepatic dysfunction, weakness, renal dysfunction, and pulmonary edema were dose limiting toxicities, occurring in two of five patients treated at 20 mg/m2/day and two of three patients treated at 12.5 mg/m2/day. The MTD was defined as 10 mg/m2/day for five days. One patient with primary resistant AML achieved complete remission. Proposed phase II studies will further define the activity of Irofulven in patients with better prognosis AML and in other hematological malignancies, both as a single agent and in combination regimens, particularly with topoisomerase 1 inhibitors.
Collapse
Affiliation(s)
- F Giles
- Department of Leukemia, The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030-4095, USA.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Murgo A, Wood KF, Gravell AE, Cheson BD. Clinical trials referral resource. ST1571. Oncology (Williston Park) 2001; 15:881-2, 885-6. [PMID: 11499689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Affiliation(s)
- A Murgo
- National Cancer Institute, USA
| | | | | | | |
Collapse
|
32
|
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19:2319-33. [PMID: 11304786 DOI: 10.1200/jco.2001.19.8.2319] [Citation(s) in RCA: 229] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-hour continuous intravenous infusion (CIV). PATIENTS AND METHODS Forty-seven patients with refractory neoplasms received UCN-01 during this phase I trial. Total, free plasma, and salivary concentrations were determined; the latter were used to address the influence of plasma protein binding on peripheral tissue distribution. The phosphorylation state of the protein kinase C (PKC) substrate alpha-adducin and the abrogation of DNA damage checkpoint also were assessed. RESULTS The recommended phase II dose of UCN-01 as a 72-hour CIV is 42.5 mg/m(2)/d for 3 days. Avid plasma protein binding of UCN-01, as measured during the trial, dictated a change in dose escalation and administration schedules. Therefore, nine patients received drug on the initial 2-week schedule, and 38 received drug on the recommended 4-week schedule. DLTs at 53 mg/m(2)/d for 3 days included hyperglycemia with resultant metabolic acidosis, pulmonary dysfunction, nausea, vomiting, and hypotension. Pharmacokinetic determinations at the recommended dose of 42.5 mg/m(2)/d for 3 days included mean total plasma concentration of 36.4 microM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h. The mean total salivary concentration was 111 nmol/L of UCN-01. One partial response was observed in a patient with melanoma, and one protracted period ( > 2.5 years) of disease stability was observed in a patient with alk-positive anaplastic large-cell lymphoma. Preliminary evidence suggests UCN-01 modulation of both PKC substrate phosphorylation and the DNA damage-related G(2) checkpoint. CONCLUSION UCN-01 can be administered safely as an initial 72-hour CIV with subsequent monthly doses administered as 36-hour infusions.
Collapse
Affiliation(s)
- E A Sausville
- Developmental Therapeutics Program Clinical Trials Unit, Medicine Branch, and Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20852, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000; 18:3513-21. [PMID: 11032593 DOI: 10.1200/jco.2000.18.20.3513] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE : To evaluate the efficacy and toxicity profiles of a combination regimen of homoharringtonine (HHT) and low-dose cytarabine (ara-C) in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) who had experienced treatment failure with interferon alfa (IFNalpha) therapy. PATIENTS AND METHODS One hundred five patients were treated: 100 in chronic phase (15 with cytogenetic clonal evolution) and five in accelerated phase. Their median age was 52 years; all had been treated unsuccessfully with IFNalpha; 94% were in late chronic phase; 43% had been exposed to ara-C and 11% had been exposed to HHT. Patients received HHT 2.5 mg/m(2) by continuous infusion daily for 5 days and ara-C 15mg/m(2) daily in two subcutaneous injections for 5 days every 4 weeks. The outcome of the 100 patients in chronic phase was compared with a previous study group of 73 patients treated with HHT alone. RESULTS Overall, the complete hematologic response (CHR) rate in chronic phase was 72%; the cytogenetic response rate was 32% (major response, 15%; complete response, 5%). Toxicities were acceptable, mostly related to moderate diarrhea (3%), headaches (3%), cardiovascular events (3%),and myelosuppression-associated complications (3% to 14%). With a median follow-up period of 25 months, the estimated 4-year survival rate was 55%. Response rates were identical with HHT plus ara-C versus HHT alone, but the survival was significantly longer with the combination after accounting for differences in the study groups and by multivariate analysis. CONCLUSION The combination regimen of HHT and ara-C is effective and safe in patients with CML who have experienced treatment failure with IFNalpha and needs to be investigated together with IFNalpha as part of front-line CML therapy. The addition of ara-C did not improve the response rates but may have improved survival, perhaps through suppression of clones related to disease transformation.
Collapse
Affiliation(s)
- H M Kantarjian
- Departments of Leukemia, Bioimmunotherapy,Biostatistics, and Blood and Bone Marrow Transplantation, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000; 27:560-77. [PMID: 11049023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Few chemotherapy agents have demonstrated activity in patients with myelodysplastic syndromes (MDS) and supportive management remains the standard of care. An increasing number of new drugs in development are being directed at specific molecular or biological targets of these diseases. Topotecan, a topoisomerase I inhibitor, has shown single-agent activity and is now being combined with other agents, including cytarabine. The aminothiol amifostine induces responses in about 30% of patients; however, its role is still being clarified. Agents that inhibit histone deacetylase and target DNA hypermethylation, thus permitting derepression of normal genes, include 5-azacytidine, decitabine, phenylbutyrate, and depsipeptide. Arsenic trioxide has demonstrated impressive activity in acute promyelocytic leukemia and preclinical data suggest the potential for activity in MDS. UCN-01 is a novel agent that inhibits protein kinase C and other protein kinases important for progression through the G1 and G2 phases of the cell cycle. Dolastatin-10 has extremely potent in vitro activity against a variety of tumor cell lines. Since its dose-limiting toxicities include myelosuppression, it is being studied in acute myelogenous leukemia (AML) and MDS. Ras may play a role in MDS, and activation of this gene and its signaling pathways may require farnesylation. Several farnesyl transferase inhibitors are now available for study in patients with MDS. An increasing body of data suggests a possible role for angiogenesis in MDS, and several antiangiogenesis agents are in clinical trials, including thalidomide, SU5416, and anti-vascular endothelial growth factor (VEGF) antibodies. Development of new drugs and regimens will be facilitated by recently developed standardized response criteria. Future clinical trials should focus on rational combinations of these agents and others with the goal of curing patients with MDS.
Collapse
Affiliation(s)
- B D Cheson
- Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
35
|
Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M, Al-Katib AM. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6:825-8. [PMID: 10741703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Bryostatin 1 is a natural product isolated from the marine bryozoan Bugula neritina in 1982 and is currently undergoing evaluation in a number of malignancies. Twenty-five patients with relapsed, low-grade non-Hodgkin's lymphoma or chronic lyphocytic leukemia (CLL) received bryostatin 1 by 72-h continuous infusion every 2 weeks at a dose of 120 microg/m2 per course. Patients who progressed while receiving bryostatin 1 alone could participate in a feasibility study by receiving vincristine administered by bolus i.v. injection immediately after the completion of the bryostatin 1 infusion. The dose of vincristine was escalated in groups of three patients as follows: level 1, 0.5 mg/m2; level 2, 1.0 mg/m2; and level 3, 1.4 mg/m2 with vincristine doses capped at 2.0 mg for all patients. Bryostatin 1 alone resulted in one complete remission and two partial remissions. Nine patients received sequential treatment with bryostatin 1 and vincristine. The addition of vincristine at a dose of 2 mg was feasible and caused the expected dose-related sensory neuropathy. Phenotypic analysis by flow cytometric analysis on pre- and post-bryostatin 1-treated peripheral blood lymphocytes revealed up-regulation in the coexpression of CD11c/ CD22 on CD20+ B cells in two of four CLL patients studied, which is consistent with in vitro findings of differentiation of CLL cells to a hairy cell phenotype.
Collapse
Affiliation(s)
- M L Varterasian
- Karmanos Cancer Institute and Wayne State University, Detroit, Michigan 48201, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Wadler S, Damle S, Haynes H, Kaleya R, Schechner R, Berkenblit R, Ladner RD, Murgo A. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. J Clin Oncol 1999; 17:1771-8. [PMID: 10561214 DOI: 10.1200/jco.1999.17.6.1771] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
PURPOSE Combined depletion of pyrimidine and purine DNA precursors has resulted in therapeutic synergism in vitro. The aims of the current study were to test this strategy in patients with refractory tumors and to assess its effects on selected nucleotide pools. PATIENTS AND METHODS A single-institution phase II trial was initiated in patients with advanced carcinomas of the stomach and pancreas. Patients had measurable disease and had no prior chemotherapy except adjuvant fluorouracil (5FU) or gemcitabine. 5FU was administered by CADD + pump at 2.6 g/m(2) intravenously by 24-hour infusion on days 1, 8, 15, 22, 29, and 36. Parenteral hydroxyurea (HU) was administered at 4.3 g/m(2) as a 24-hour infusion concurrently with 5FU. Interferon alfa-2a (IFN-alpha2a) was administered at 9 million units subcutaneously on days 1, 3, and 5 each week. No drug was administered in weeks 7 and 8. Pharmacodynamic studies were performed to assess drug effects on levels of deoxyuridine triphosphate (dUTP) and thymidine triphosphate (TTP) pools in peripheral-blood mononuclear cells (PBMCs) before and 6 hours after treatment using a highly sensitive DNA polymerase assay. RESULTS There were 53 patients enrolled onto the study (gastric carcinoma, 31; pancreatic carcinoma, 22). The median age was 61 years, with 22% of patients > or = 70 years old. The predominant grade 3 to 4 toxicities were leukopenia (49%), granulocytopenia (55%), and thrombocytopenia (22%). Severe diarrhea occurred in 12%, mucositis in 0%, and vomiting in 10% of patients. Patients > or = 70 years had no greater incidence of toxicities. Among the 30 assessable patients with gastric carcinoma, there were two (7%) complete responders and 11 (37%) partial responders (median duration, 7 months). Among the 21 assessable patients with pancreatic carcinoma, there was one responder. Median survival among all patients with gastric carcinoma was 10 months and 13 months for patients with pancreatic carcinoma. Twenty-three patients had samples studied for levels of dUTP and TTP. There was no change in the levels of TTP before and after treatment. Furthermore, dUTP was detected in only five of 28 samples after treatment with no increase in the dUTP/TTP ratio. CONCLUSION Combination therapy with high-dose, weekly infusional HU and 5FU with IFN-alpha2a modulation was well-tolerated with activity in gastric cancer. Patients > or = 70 years tolerated therapy as well as younger patients. This was the first study to correlate levels of TTP and dUTP after treatment with clinical outcome. In PBMCs used as a surrogate tissue, HU abrogated the 5FU-induced increase in dUTP levels without reversing the overall efficacy of the regimen.
Collapse
Affiliation(s)
- S Wadler
- Departments of Oncology, Surgery, and Radiology, Montefiore Medical Center, and the Albert Einstein Cancer Center, Bronx, NY 10467, USA.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Murgo A, Cannon DJ, Blatner G, Cheson BD. Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Williston Park) 1999; 13:233, 237-8. [PMID: 10079472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|
38
|
Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651-6. [PMID: 9250225 DOI: 10.1001/archinte.157.15.1651] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Sporadic single case reports linking glucocorticoidlike activity to megestrol acetate have been reported in the literature. These findings have important implications for patient care. Adverse drug experience reports to the US Food and Drug Administration from 1984 through 1996 and a MEDLINE search of the literature from 1984 through 1996 provided the case reports. Five cases of Cushing syndrome, 12 cases of new-onset diabetes, and 16 cases of adrenal insufficiency were identified in association with megestrol therapy. Twelve cases in which preexisting diabetes was exacerbated and 17 cases of possible adrenal insufficiency were identified. Therapy with megestrol can result in clinical manifestations of glucocorticoidlike activity, including Cushing syndrome, diabetes, and adrenal insufficiency. Clinicians need to be aware of this association as these complications can be life-threatening if not recognized.
Collapse
Affiliation(s)
- M Mann
- Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Md, USA
| | | | | | | | | | | |
Collapse
|
39
|
Al-Kawas FH, Murgo A, Foshag L, Shiels W. Lymphadenopathy in celiac disease: not always a sign of lymphoma. Am J Gastroenterol 1988; 83:301-3. [PMID: 3344733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A patient with celiac disease and mesenteric adenopathy discovered on computerized scanning of the abdomen is described. Lymphadenopathy resolved more than 6 months after the institution of a gluten-free diet. Adenopathy without evidence of lymphoma may be part of the clinical manifestations of patients with celiac disease. Follow-up with computerized tomography may be an option in patients with low clinical suspicion for lymphoma.
Collapse
Affiliation(s)
- F H Al-Kawas
- Department of Medicine, West Virginia University School of Medicine, Morgantown
| | | | | | | |
Collapse
|
40
|
|